Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Real-world experience with idarucizumab for dabigatran reversal in a third-level hospital
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: DOMINGUEZ BRAHONA, Ana (Hospital Virgen de la Salud, Pharmacy)
- Co-author(s): Ana Dominguez Barahona
Cristina Blázquez Romero
Helena Quirós Ambel
Ana García Sacristán
Silvia Gonzalez Suarez
Ana Rosa Rubio Salvador
Nuria Labrador Andújar
Paloma Moya Gomez
BackgroundIdarucizumab has been approved for use when reversal of the anticoagulant effects of dabigatran is needed for urgent procedures or in patients with life-threatening bleeding.
MethodsObservational, descriptive, retrospective (April 2017-April 2018) and longitudinal study of patients treated with idarucizumab in a general hospital of 650.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019